MiNK Therapeutics Enters $5.8 M PIPE and Appointment of Board Observer

May 13, 2024

DENVER, Colo., May 13, 2024 (247marketnews.com)- MiNK Therapeutics, Inc. (NASDAQ:INKT) entered into a $5.8 million private placement financing (PIPE) of 4,640,000 shares of its common stock, at a price of $1.25 per share, a 25% premium, which is earmarked for accelerating the clinical trials of MiNK-215

“This funding will help advance our unique armored iNKT therapy MiNK-215,” commented MiNK’s President and Chief Executive Officer, Jennifer Buell. “MiNK-215 is a novel cell therapeutic with the potential to overcome the limitations of traditional immune checkpoint inhibitors in solid tumors. Recent data highlighted MiNK-215’s activity to eradicate tumor cells in a model of MSS colorectal cancer with metastatic liver disease, a critical and growing area of unmet need. We are excited to partner with GKCC and committed to advancing our mission of reshaping the cell therapy landscape.”

MiNK additionally appointed Yekaterina (“Katie”) Chudnovsky as Board Observer.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (INKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.